Practical recommendations of the EBMT for the use of CAR-T cells

**Approved therapies**
- Tisagenlecleucel (Kymriah™)
- Axicabtagene ciloleucel (Yescarta™)

**TCR**
- anti-CD19
- anti-CD28

**Treatment**
- Refractory/relapsed Acute Lymphoblastic Leukaemia
- Relapsed/refractory Diffuse Large B-cell Lymphoma
- Relapsed/refractory high-grade B-cell Lymphoma
- Primary Mediastinal B-cell Lymphoma

---

Practical recommendations of the European Society of Blood and Marrow Transplantation

- Patient eligibility
- Screening laboratory tests and imaging and work-up prior to leukapheresis
- How to perform leukapheresis
- Bridging therapy
- Lymphodepleting conditioning
- Product receipt and thawing
- Infusion of chimeric antigen receptor T-cells

- Short-term complications
- Antibiotic prophylaxis
- Medium-term complications
- Long-term follow-up
- Post-authorisation safety surveillance
- Regulatory issues

Yakoub-Agha et al. Haematologica, 2020